SBC Medical Group Holdings Incorporated reported its financial results for the first quarter of 2026. Revenue for the quarter reached $43.06 million, representing a 9% year-over-year decline, yet it slightly surpassed market expectations of $41.65 million. GAAP earnings per share were $0.11, exceeding the anticipated $0.09. Net profit stood at $11.31 million, a decrease of 47% compared to the same period last year, with the net profit margin narrowing to 26%. EBITDA was $18.39 million, down 26% year-over-year, resulting in an EBITDA margin of 43%.

The company's CEO attributed the revenue decline primarily to the structural adjustment of franchise fees implemented in April 2025. Excluding this structural change, core business performance remained solid.

Management emphasized during the earnings call that the year-over-year impact of the fee structure adjustment is expected to gradually diminish, creating conditions for subsequent margin improvement. Operational indicators point to a continuously positive fundamental trend: the number of franchise outlets increased to 284, up by 33 year-over-year; the customer base over the past 12 months reached 6.76 million, a 10% increase; and the repeat visit rate stood at 72%.

Earnings per share for the period were $0.11, higher than the market consensus of $0.10.

SBC Medical Group Holdings Incorporated is pursuing margin enhancement and global expansion through two main pathways: the deployment of AI technology and strategic mergers and acquisitions. The company continues to advance its multi-brand strategy in aesthetic dermatology, expand its non-aesthetic medical services, and deepen its operational foundation in overseas markets. Management also indicated that the company will explore opportunities in the longevity medicine market and further optimize service capabilities through AI, with the goal of building a sustainable healthcare platform.